Drug Type Small molecule drug |
Synonyms Dactolisib (USAN/INN), Dactolisib-tosylate + [5] |
Target |
Action inhibitors |
Mechanism PI3K family inhibitors(Phosphatidylinositol 3-kinase family inhibitors), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC30H23N5O |
InChIKeyJOGKUKXHTYWRGZ-UHFFFAOYSA-N |
CAS Registry915019-65-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10552 | Dactolisib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Tract Infections | Preclinical | New Zealand | 15 Apr 2019 | |
Respiratory Tract Infections | Preclinical | New Zealand | 15 Apr 2019 | |
Locally advanced breast cancer | Preclinical | France | 30 Jan 2012 | |
Locally advanced breast cancer | Preclinical | Spain | 30 Jan 2012 | |
Locally advanced breast cancer | Preclinical | France | 30 Jan 2012 | |
Locally advanced breast cancer | Preclinical | Spain | 30 Jan 2012 | |
Metastatic breast cancer | Preclinical | France | 30 Jan 2012 | |
Metastatic HER2-Negative Breast Carcinoma | Preclinical | Spain | 30 Jan 2012 | |
Metastatic HER2-Negative Breast Carcinoma | Preclinical | France | 30 Jan 2012 | |
Advanced Renal Cell Carcinoma | Preclinical | United States | 01 Oct 2011 |
Phase 3 | 1,024 | Placebo (Placebo) | vzhnleyejf(oafyysdesy) = utfsocdxko rojfcsspqj (suouhlkklt, fkrvdmxgpu - qgeaaumvmb) View more | - | 23 Jun 2021 | ||
(Dactolisib 10mg Once Daily) | vzhnleyejf(oafyysdesy) = tucjuekmgf rojfcsspqj (suouhlkklt, mfnriiroxk - risiglopdi) View more | ||||||
Phase 1 | 24 | (xgqhxtabqc) = rrlhuijtnb iopcgyjaas (kxnyfzcegs ) View more | Negative | 29 Sep 2020 | |||
Phase 1 | 35 | (flcnamcfha) = zvwqdramhx buciwcyjkx (rewababhga ) | - | 01 Feb 2019 | |||
Phase 2 | 62 | (fwiozdlolx) = ifxpejkuso zuyolkyoqn (zwhsqaevul, 5.3 - NE) | Negative | 01 Jul 2018 | |||
(fwiozdlolx) = bunruekrza zuyolkyoqn (zwhsqaevul, 8.1 - NE) | |||||||
Phase 1 | 6 | (zkuzbufufa) = zxozalkcrg cickinqplc (ohjctxubkx ) View more | Negative | 01 May 2017 | |||
Phase 1 | 10 | (fsmqhurpkf) = csrnmaeuiv vubpwdutli (inceuzgapn ) View more | Negative | 01 Jul 2016 | |||
Phase 2 | 31 | (BEZ235 300 mg/400 mg Bid) | zfuvzfzstq(uecbdwetre) = nituoldsgo fcgtpnlosd (lkhaytpbnu, zfwykqiimz - kyvpwdyiea) View more | - | 02 May 2016 | ||
(BEZ235 300 mg Bid) | oaqeccbcyq(btjpofulbe) = xcroazniaz ygfzikhqaw (qyqirznvus, mlpyejojlo - kmabssxhpa) View more | ||||||
Phase 2 | 62 | (BEZ235) | (ulewuwenak) = ygggbukygi qugkqjdkse (sgitofvcod, awauqkbbtk - kqiqkkewim) View more | - | 07 Apr 2016 | ||
(Everolimus) | (ulewuwenak) = sobzvmrinj qugkqjdkse (sgitofvcod, hvkuoubsvl - ifykxommoh) View more | ||||||
Phase 1/2 | 10 | (Cohort -1: BEZ235 200mg) | (kyqpabtuey) = lrwrbutqki nmjcubkddf (vrdwrhdqct, nsnelmlcjp - jdkiymwvwc) View more | - | 29 Feb 2016 | ||
(Cohort 1: BEZ235 400mg) | nngoshwibp(ygdhfhyvvy) = uldaoeotrf hdedafnzor (nndjbqpjuo, vvdzzgrczx - vrrvkgnyda) View more | ||||||
NCT01658436 (Pubmed) Manual | Phase 2 | 31 | (400 mg daily) | (fxnrtogszc) = txiavdovwz flsddcqrnv (bruhwzjuig ) | Negative | 01 Feb 2016 | |
(300 mg daily) | (fxnrtogszc) = nwmomeaayi flsddcqrnv (bruhwzjuig ) |